Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Methacrylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL29560432 | 1.00 | ALDH1A1 (0.40) | ALDH1A1GAASMN1; SMN2CYP3A4CYP1A2 | |
| Methacrylic Acid SCHEMBL8110276 | 0.85 | KDM4E (0.42) | ALDH1A1CYP2C9LMNAMAPTHPGD | |
| Methacrylic Acid SCHEMBL301490 | 0.85 | KDM4E (0.42) | ALDH1A1CYP2C9LMNAMAPTHPGD | |
| Acetone SCHEMBL11802482 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL11175970 | 0.83 | TDP1 (0.50) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Acrylic Acid SCHEMBL27650681 | 0.83 | ALDH1A1 (0.43) | ALDH1A1GAASMN1; SMN2CYP3A4CYP1A2 | |
| SCHEMBL3146710 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Methacrylic Acid SCHEMBL3020182 | 0.82 | KDM4E (0.41) | ALDH1A1CYP2C9LMNAMAPTHPGD | |
| Acetamide SCHEMBL27724259 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Styrene SCHEMBL1728767 | 0.80 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218719-A1 | MATRIX COMPOSITION COMPRISING (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-14 | — | — | US | claimed |
| US-9149439-B2 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2015-10-06 | — | — | US | claimed |
| US-20090060848-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | JOSHI YATINDRA | 2009-03-05 | — | — | US | claimed |
| EP-1954282-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | claimed |
| US-20070148247-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA | 2007-06-28 | — | — | US | claimed |
| WO-2007059500-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| US-20070048379-A1 | Valproate tablet | GUO MINTONG | 2007-03-01 | — | — | US | claimed |
| WO-2006102446-A2 | MULTI-PARTICULATE, MODIFIED-RELEASED COLONIC COMPOSITION | SANDOZ AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-20060210631-A1 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2006-09-21 | — | — | US | claimed |
| WO-2005077342-A1 | ENTERICALLY COATED LANSOPRAZOLE MICROTABLETS | SANDOZ AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-20050181052-A1 | Lansoprazole microtablets | PATEL SATISHKUMAR A (US) | 2005-08-18 | — | — | US | claimed |
| US-20040042964-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2004-03-04 | — | — | US | claimed |
| US-20020187192-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2002-12-12 | — | — | US | claimed |
| WO-2002087558-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | claimed |
| EP-1019029-A1 | MONOLITHIC SYSTEM CONTAINING ONE OR MORE DRUGS, CONSISTING OF THREE LAYERS WITH DIFFERENT RELEASE MECHANISMS | CHIESI FARMACEUTICI S.p.A. (IT) | 2000-07-19 | — | — | EP | claimed |
| WO-1999017745-A1 | MONOLITHIC SYSTEM CONTAINING ONE OR MORE DRUGS, CONSISTING OF THREE LAYERS WITH DIFFERENT RELEASE MECHANISMS | CHIESI FARMACEUTICI S.P.A. (IT) | 1999-04-15 | — | — | WO | claimed |
| US-5464633-A | Core containing active substance to be released in gastric or intestinal tract, polymer which swells and/or gels and/or erodes on contact with water, and adjuvants and excipients; layer applied to core by compression process | JAGOTEC AG (CH) | 1995-11-07 | — | — | US | claimed |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-1995020946-A1 | BILAYERED AMOXYCILLIN TABLETS | SMITHKLINE BEECHAM PLC (GB) | 1995-08-10 | — | — | WO | disclosed |
| CN-1082888-A | Be used to prepare and comprise the method for release oral pharmaceutical dosage form that its dissolubility depends on the active substance of pH value | L C PHARCHEM LTD (CY) | 1994-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | HTR5A, CHRNA5, HTR1A | ALDH1A1 90/4885GAA 575/4885SMN1; SMN2 655/4885 |
| US-20220218719-A1 | MATRIX COMPOSITION COMPRISING (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | RIPK1, RIPK2, RIPK4 | ALDH1A1 4546/4885GAA 1912/4885SMN1; SMN2 1318/4885 |
| US-20070048379-A1 | Valproate tablet | CACNA1A, SUCLG2, CACNA1G | ALDH1A1 1386/4885GAA 434/4885SMN1; SMN2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.